Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today a new partnership with CardioNavix, LLC aimed at improving patient access to cardiac PET imaging, an important diagnostic test for the detection of coronary artery disease (CAD).
| MONROE TOWNSHIP, N.J., March 29, 2021 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today a new partnership with CardioNavix, LLC aimed at improving patient access to cardiac PET imaging, an important diagnostic test for the detection of coronary artery disease (CAD). This new program, the Bracco Mobile Isotope Service, will enable more patient care sites, such as community hospitals, physician practices and outpatient imaging centers, to provide cardiac PET imaging.
Kim McDaniel, Sr. Director, Nuclear Medicine Sales and Market Support said, “Establishing a cardiac PET imaging program requires significant upfront and ongoing costs that a provider must be able to recover. This can make the modality challenging to implement for institutions with lower patient volumes due to location or the need to share equipment with oncology studies. This new program will help lower the upfront cost and business risk, to allow more healthcare providers to offer this important diagnostic test. Our Bracco Mobile Isotope Service and partnership with CardioNavix is another example of our commitment to increase patient access to cardiac PET imaging.” Bracco Mobile Isotope Service On-Demand Delivery Program Increases Flexibility, Decreases Upfront Business Risk The Bracco Mobile Isotope Service with CardioNavix provides a solution with on-demand generator delivery service, expanding access to patient care sites with low volume. The generator and all necessary equipment are delivered as needed, so the site pays only for the days they wish to image patients. It can be ideal for healthcare providers imaging on a part-time schedule, or those located in less populous areas. It also allows sites to ramp up and grow into a full-time traditional generator delivery schedule as their number of procedures increases. Lon Wilson, President and Radiation Safety Officer of CardioNavix, explains, “Cardiac PET imaging is recognized as the test of choice for non-invasive cardiac perfusion imaging. It meets important goals for the Centers for Medicare and Medicaid Services (CMS) including supporting positive patient outcomes with lower cost and high patient satisfaction. We are thrilled to partner with Bracco Diagnostics to deliver cardiac PET to imaging labs nationwide. Expanding access to cardiac PET imaging by lowering the financial barriers to entry is a win-win for healthcare providers and their patients. We anticipate significant interest in the program and believe that our agreement with Bracco Diagnostics will help more providers offer cardiac PET imaging to their patients.” Bracco and CardioNavix LLC: Committed to Patient Care Indications and Usage for CARDIOGEN-82® (Rubidium Rb 82 Generator) IMPORTANT SAFETY INFORMATION: WARNING: HIGH LEVEL RADIATION EXPOSURE WITH USE OF INCORRECT ELUENT AND FAILURE TO FOLLOWTHE ELUATE TESTING PROTOCOL High Level Radiation Exposure with Use of Incorrect Eluent
Excess Radiation Exposure with Failure to Follow the Eluate Testing Protocol
Please see full Prescribing Information for CARDIOGEN-82 (Rubidium Rb 82 Generator) including boxed WARNING at https://imaging.bracco.com/us-en/products/nuclear-medicine-radiopharmaceuticals/cardiogen-82. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. CARDIOGEN-82 is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831, by GE Healthcare, Medi-Physics, Inc., South Plainfield, NJ 07080. CARDIOGEN-82 is a registered trademark of Bracco Diagnostics Inc. About CardioNavix CardioNavix recognizes the need for a Rubidium-82 generator for flexible use and possesses the versatility to have the infusion system there on the days you need it and not on the days you don’t - including weekends. CardioNavix is the only company in the nation equipped to deliver the CardioGen-82® infusion system to healthcare facilities for daily use with its patented transport device. CardioNavix has helped hundreds of physicians and hospitals successfully introduce cardiac PET imaging to their patient care sites. A first in the industry, CardioNavix supports medical providers who may not have the necessary volume of studies for a full-time on-site generator to now provide the most advanced non-invasive perfusion study available to their patients. To learn more about CardioNavix, visit www.cardionavix.com. For additional information about Bracco’s products, and for full prescribing information, please visit https://imaging.bracco.com/us-en. About Bracco Imaging S.p.A. Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. Bracco Imaging has a strong presence in key geographies: North America, China, Europe, Japan, Brazil, Mexico and South Korea. Bracco Imaging’s manufacturing plants operate in full compliance with the best practices and sustainable eco-friendly production processes. Manufacturing sites are based in Italy, Switzerland, Germany, Canada, China, Japan, and the USA. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. R&D activities are located in three centers based in Italy, Switzerland and the USA. To learn more about Bracco Imaging, visit www.braccoimaging.com. Press Contact:
SOURCE Bracco Diagnostics Inc. |
View original content to download multimedia:
